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14S Abstracts June Supplement 2014D (P ¼ .01). The long-term primary patency rate after 24
months for the total population was 87.9% (88.0% for
TASC A, 88.5% for TASC B, 91.9% for TASC C, and
83.1% for TASC D, no statistically signiﬁcant difference
was shown when comparing these groups). The 24-
month primary patency rates were 92.1% for patients
treated with the self-expanding stent, 85.2% for patients
treated with the balloon-expandable stent, and 75.3%
for patients treated with a combination of both stents
(P ¼ .06). Univariate and multivariable regression ana-
lyses using Cox proportional hazards model identiﬁed
only kissing stent conﬁguration (P ¼ .0012) and obesity
(P ¼ .0109) as independent predictors of restenosis
(primary patency failure). Interestingly, because all
TASC groups enjoyed high levels of patency, neither
TASC category nor lesion length was predictive of
restenosis.
Conclusions: The 24-month data from this large, pro-
spective, multi-center study conﬁrm that endovascular
therapy may be considered the preferred ﬁrst-line treat-
ment option of aorto-iliac lesions, irrespectively of TASC
lesion category.
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Objectives: Open (OPAR) and endovascular (EPAR)
repair are both used to treat popliteal artery aneurysms
(PAA). We assessed outcomes of both modalities in the
treatment of asymptomatic PAA.
Methods: VQI databases (2010-2013) were queried
for patients undergoing asymptomatic PAA repair using
OPAR and EPAR. The groups were compared with
respect to demographics, medical history, and procedural
characteristics. Outcomes included major adverse limb
events (MALE), MALE and postoperative death
(MALE-POD), popliteal artery patency loss, and length
of stay (LOS). Proportional hazard Cox regression was
used to compare the outcomes across the treatment groups
and multivariate regression with backward elimination
procedure (a ¼ .5) was used to construct parsimonious
models.
Results: We identiﬁed 390 patients (221 OPAR, 169
EPAR). Preoperative comorbidities were similar between
the two groups, except for a higher rate of congestive
heart failure (11.8% vs 5.9%, P ¼ .043) and chronic
obstructive pulmonary disease (19.5% vs 11.8%, P ¼
.045) in the EPAR group. No in-hospital mortality was
observed. LOS was longer in the OPAR group(3.8 6 2.5 vs 1.4 6 1.9 days; P < .001). OPAR was asso-
ciated with lower hazard of MALE (0.35; 95% conﬁdence
interval [CI], 0.14-0.86), MALE-POD (0.28; 95% CI,
0.13-0.63), and popliteal artery patency loss (0.35; 95%
CI, 0.16-0.75). OPAR patients had a signiﬁcantly better
MALE-free survival (Fig).
Conclusions: This retrospective analysis suggests that
OPAR is associated with better outcomes than EPAR. Ul-
timately, the ongoing, adequately powered open vs endo-
vascular repair of PAA (OVERPAR) trial will deﬁnitively
compare these procedures.
Fig.
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Objectives: The use of drug-eluting balloons
(DEBs) in treating de novo arteriosclerotic lesions is
well established. However, the effectiveness of this tech-
nology in femoropopliteal restenosis has to be demon-
strated. The purpose of the study was to assess the
efﬁcacy of paclitaxel-DEB in restenotic (stented ¼ ISR
and nonstented) vs de novo stenotic femoropopliteal
arteries.
Methods: Patients undergoing femoropopliteal
endovascular intervention with DEB for restenosis (RE)
or de novo stenosis (DN) were prospectively enrolled.
Excluded were patients with additional atherectomy.
Clinical parameters (age, risk, risk factors) were compara-
ble within the groups apart from the treated lesion
lengths (RE, 130 6 65 mm; DN, 115 6 71 mm; P ¼
.041). Primary end point was the primary patency (PP)
rate at 12 months. Secondary end points were secondary
sustained clinical improvement measured by Rutherford
classiﬁcation and clinically driven target lesion revascular-
ization (TLR).
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for intermittent claudication (IC, n ¼ 8 [8%]) or critical
limb ischemia (CLI; n ¼ 89 [92%]) in 88 patients. Lesions
were de novo (n ¼ 37 [38%]) or restenosis (n ¼ 60 [64%],
with n ¼ 41 [68%] ISR). Overall PP rate was 77.2% and
57.8% at 6 and 12 months. PP rate of de novo group
was signiﬁcantly (P < .05) higher compared with the reste-
nosis group after 6 (94.5% vs 77.2%) and 12 months
(85.1% vs 57.8%). After 12 months secondary TLR was
signiﬁcantly higher in RE (23.7% vs 4.1% in DN; P <
.001). Sustained clinical improvement was 79.4% in RE
and 66.7% in DE (P ¼ .34).
Conclusions: DEB is an effective therapy for femoro-
popliteal lesions. The results of DEB for restenosis are infe-
rior compared with de novo stenosis. Nevertheless,
outcomes after DEB for restenosis seem to be comparable
with technically more demanding ISR strategies.
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Objectives: There are no deﬁned criteria for the de-
gree of venous compression leading to venous thoracic
outlet syndrome (vTOS). Our goal was to evaluate the re-
lationships between subclavian vein stenosis and symptoms
in vTOS using contrast venography and intravascular ultra-
sound (IVUS).
Methods: Subclavian veins of consecutive patients
presenting with vTOS were evaluated by venography and
IVUS in the index and contralateral limbs. Venograms
were classiﬁed as normal, stenotic, or occluded. Venogram
and IVUS measurements were made at two locations:
lateral margin of the ﬁrst rib (S1) and site of maximal
compression (S2). Venography provided cranial-caudal
(CC) dimensions. IVUS measurements included: ante-
rior-posterior, CC dimensions (mm), and cross-sectional
area (mm2). The ratio of these determined percentage of
stenosis. Postoperatively, limbs were reevaluated by venog-
raphy and IVUS.
Results: Forty-ﬁve limbs from 23 patients were evalu-
ated. Twenty-three limbs underwent TOS decompression
and were evaluated postoperatively. IVUS and venogram
data are presented in the Table.
Conclusions: vTOS symptoms are related to the pres-
ence of high-grade stenosis and best deﬁned by IVUS.
Asymptomatic patients demonstrate unexpected luminal
reduction, which appears nonpathologic. Compared with
venography, IVUS provides a more detailed evaluation
of the subclavian vein. The greatest change in venous
dimension by IVUS is in the anterior-posterior plane and
is not seen on venography. IVUS offers the potential to
reﬁne criteria identifying critical stenosis at the thoracic
outlet.Table. Venogram and intravascular ultrasound (IVUS)
data for all subjects presenting with venous thoracic
outlet syndrome (vTOS) symptoms
Pre-op Post-op Post-opPatients (No.)Pre-op venogram IVUS venogram IVUSReading
CC
Stenosis (%)Area
stenosis (%)CC
Stenosis (%)Area
stenosis (%)Symptomatic
3 Normal 24.1 54.0 N/A N/A
12 Stenotic 39.0 81.1 31.2 40.3
11 Occluded 100 100 34.9 57.1Asymptomatic
11 Normal 8.4 59.0 N/A N/A
8 Stenotic 48.7 72.6 N/A N/AAuthor Disclosures: B. G. DeRubertis: Nothing to
disclose; S. M. Farley: Nothing to disclose;H. A. Gelabert:
Nothing to disclose; J. C. Jimenez: Nothing to disclose;
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Objectives: The impact of anatomic suitability for endo-
vascular aneurysm repair (EVAR) as it relates to mortality for
ruptured abdominal aortic aneurysm (rAAA) is unknown.We
reviewed our experience managing rAAA patients with
emphasis onEVARcandidacy as it relates to 30-daymortality.
Methods: This study included all patients with rAAA
between January 1, 2002, and October 31, 2013 from a
single institution. All images were reviewed by a physician
blinded to outcome/procedure with speciﬁc notation
made on EVAR candidacy (aortic neck diameter and
length). Data were compared using Pearson c2 with signif-
icance set at P < .05.
Results: Of 303 patients with rAAA, 235 (78%) had a
computed tomography scan, 215 were “evaluable,” and
156 (73%) were considered EVAR candidates. Mean aneu-
rysm diameter, aortic neck diameter, and length were 82.4
mm (range, 37-182 mm), 26.7 mm (range, 15-65 mm),
and 17.2 (range, 0-105 mm). The Table shows 30-day
mortality by procedure and EVAR candidacy. For patients
undergoing EVAR, EVAR candidates had a signiﬁcant sur-
vival advantage (77.6% vs 0%; P ¼ .0001). For patients un-
dergoing open repair, there was no difference in mortality
based on EVAR candidacy (49.2% vs 46.9%; P ¼ .82).
Conclusions: Candidates for EVAR who undergo
EVAR for rAAA have a signiﬁcant survival advantage
over those undergoing open repair and those undergoing
EVAR without suitable anatomy. Mortality for any open
repair is high and does not differ based on EVAR candi-
dacy. Those patients with anatomy unsuitable for EVAR
should not undergo an attempt at endovascular repair
because the result is uniformly fatal at 30 days.
